Hoffman Rea. Hematology - Basic principles and Practice. Elsevier; 2022.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.
Döhner H, Longo DL, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52. https://doi.org/10.1056/NEJMra1406184.
Ishii H, Yano S. New therapeutic strategies for adult Acute Myeloid Leukemia. Cancers. 2022;14(11). https://doi.org/10.3390/cancers14112806.
Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL) - a review of the literature. Oncotarget. 2020;11(11):992–1003.
Article PubMed Central Google Scholar
Granata R. Peripheral activities of growth hormone-releasing hormone. J Endocrinol Investig. 2016;39(7):721–7. https://doi.org/10.1007/s40618-016-0440-x.
Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and potential therapeutic applications of growth hormone-releasing hormone agonists. Endocrinology. 2019;160(7):1600–12. https://doi.org/10.1210/en.2019-00111.
Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, et al. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides. 2014;52:104–12. https://doi.org/10.1016/j.peptides.2013.12.010.
Cui T, Jimenez JJ, Block NL, Badiavas EV, Menocal LR, Granda AV, Cai R, Sha W, Zarandi M, Perez R, Schally AV. Agonistic analogs of GHRH promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget. 2016;7:52661–72.
Article PubMed Central Google Scholar
Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002;13(7):299–303. https://doi.org/10.1016/s1043-2760(02)00613-6.
Kiaris H, Schally AV, Varga JL, Groot K, Armatis P. Growth hormone-releasing hormone- An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A. 1999;96:14894–8.
Article PubMed Central CAS Google Scholar
Cui T, Schally AV. Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget. 2018;9(47):28745–56. https://doi.org/10.18632/oncotarget.25676.
Article PubMed Central Google Scholar
Kahan Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, Schally AV. Expression of GHRH messenger RNA and the presence of bio active GHRH in human breast, endometrial and ovarian cancers. J Clin Endocrinol Metab. 1999;84(2):582–9.
Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A. 2005;102(48):17424–9. https://doi.org/10.1073/pnas.0506844102.
Article PubMed Central CAS Google Scholar
Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone releasing hormone antagonist MZ-4-71 inhibits in-vivo proliferation of cak- ii renal adenocarcinoma. Proc Natl Acad Sci U S A. 1997;94:5810–3.
Article PubMed Central CAS Google Scholar
Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, et al. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer. 2002;95(8):1735–45. https://doi.org/10.1002/cncr.10865.
Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 2012;3(9):988–97. https://doi.org/10.18632/oncotarget.634.
Article PubMed Central Google Scholar
Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs. 2001;12(9):761–8. https://doi.org/10.1097/00001813-200110000-00008.
Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer. 2000;36(1):128–36. https://doi.org/10.1016/s0959-8049(99)00230-0.
Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M et al. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proceedings of the National Academy of Sciences. 2012;109(5):1655-60. https://doi.org/10.1073/pnas.1120588109
Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone-releasing hormone anatognists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A. 2003;100:1250–5.
Article PubMed Central CAS Google Scholar
Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer. 2000;82(10):1724–31. https://doi.org/10.1054/bjoc.2000.1223.
Article PubMed Central CAS Google Scholar
Schally AV, Wang H, He J, Cai R, Sha W, Popovics P et al. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. Proceedings of the National Academy of Sciences. 2018;115(47):12028-33. https://doi.org/10.1073/pnas.1813375115
Stephanou A, Knight RA, Lightman SL. Production of a growth hormone-releasing hormone-like peptide and its mRNA by human lymphocytes. Neuroendocrinology. 1991;53(6):628–33.
Khorram O, Garthwaite M, Golos T. The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab. 2001;86(7):3157–61. https://doi.org/10.1210/jcem.86.7.7652.
Keller G, Schally AV, Groot K, Toller GL, Havt A, Koster F, Armatis R, Halmos G, Zarandi M, Varga JL, Engel JB. Effective treatment of experimental human non-hodkin’s lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 2005;102(30):10628–33.
Article PubMed Central CAS Google Scholar
Jimenez JJ, DelCanto GM, Popovics P, Perez A, Vila Granda A, Vidaurre I, et al. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. Br J Haematol. 2018;181(4):476–85. https://doi.org/10.1111/bjh.15207.
Chale RS, Rodriguez M, Almieda SM, Sclatter S, Singareddy S, Schally AV, Jimenez JJ. Synergistic effects of MIA-602 and its potential for use in ATRA/ATO Resistant APL. Cancer Res. 2023;83:385.
Chale RS, Almeida SM, Rodriguez M, Jozic I, Gaumond SI, Schally AV, et al. The application of GHRH antagonist as a treatment for resistant APL. Cancers. 2023;15(12). https://doi.org/10.3390/cancers15123104.
Chale RS, Singareddy A, Sclater S, Almeida SM, Lens A, Schally AV, et al. K562: an In-Vitro AML Model for studying synergistic effects of Doxorubicin & MIA-602. Clin Lymphoma Myeloma Leuk. 2022;22. https://doi.org/10.1016/s2152-2650(22)01296-4.
Gaumond SI, Abdin R, Costoya J, Schally AV, Jimenez JJ. Exploring the role of GHRH antagonist MIA-602 in overcoming doxorubicin-resistance in acute myeloid leukemia. Oncotarget. 2024.
Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, et al. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate. 2008;68(16):1763–72. https://doi.org/10.1002/pros.20843.
Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G. Antagonists of GHRH and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian Cancer cell line xenografted into Nude mice. J Cllinical Endocrinol Metabolism. 2001;86(5):2144–52.
Zarandi M, Cai R, Kovacs M, Popovics P, Szalontay L, Cui T, et al. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides. 2017;89:60–70. https://doi.org/10.1016/j.peptides.2017.01.009.
Gan J, Ke X, Jiang J, Dong H, Yao Z, Lin Y, Lin W, Wu X, Yan S, Zhuang Y, Chu WK, Cai R, Zhang X, Cheung HS, Block NL, Pang CP, Schally AV, Zhang H. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK-1-STAT3/NF-kB signaling. Proc Natl Acad Sci U S A. 2016;113(51):14745–50.
Article PubMed Central CAS Google Scholar
Kiaris H, Schally AV. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1999;96(1):226–31. https://doi.org/10.1073/pnas.96.1.226.
Article PubMed Central CAS Google Scholar
Frohman LA, Szabo M. Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res. 1981;74:259–71.
Comments (0)